Open Save New
FeedNavigator / National Library of Health Sciences
Tutkijat / Oulu
AddAla-Kokko, L.
AddAla-Kokko, T(ero)
AddAla-Korpela, M(ika)
AddAlahuhta, S.
AddAlén, M(arkku)
AddAntikainen, R.
AddAnttonen, V(uokko)
AddBiancari, F(austo)
AddBloigu, R(isto)
AddEskelinen, S.
AddFlinkkilä, T(apio)
AddHakkola, J.
AddHallman, M.
AddHartikainen, A(nna)-L(iisa)
AddHausen, H.
AddHautala, N(ina)
AddHautala, T(imo)
AddHeape, A.
AddHerzig, K(arl)-H(einz)
AddHillbom, M.
AddHiltunen, J.K.
AddHörkko, S.
AddHuikuri, H(eikki)
AddHukkanen J(anne)
AddIgnatius, J.
AddIsohanni, M.
AddJaakkola, J.
AddJaakkola, M(aritta) S.
AddJaakola, V-P.
AddJämsä, T(imo)
AddJanhonen, S.
AddJartti, T(uomas)
AddJärvelin, M(arjo)-R(iitta)
AddJokelainen, J(ari)
AddJuffer, A(ndré) H.
AddJunttila, J(uhani)
AddJuvonen, T.
AddKaarteenaho, R(iitta)
AddKajantie, E(ero)*(THL/OY)
AddKarppinen (Koivunen), P(eppi)
AddKarppinen, J(aro)
AddKarttunen, T.J.
AddKeinänen-Kiukaanniemi, S(irkka)
AddKerkelä, R(isto)
AddKesäniemi, Y(rjö) A(ntero)
AddKettunen, J(ohannes)
AddKietzmann, T(homas).
AddKivirikko, K.I.
AddKnuuttila, M.
AddKoivukangas, J.
AddKursula, P(etri)
AddKyngäs, H.
AddLarivaara, P.
AddLarmas, M.
AddLehenkari, P(etri)
AddLehtiö, L(ari)
AddLeppilahti, J.
AddLuukinen, H.
AddMainio A
AddMajamaa, K.
AddMäki, P(irjo)
AddMäkikallio, T(imo) H.
AddMännikkö, M(inna)
AddManninen, A(ki).
AddMartikainen, H(annu)
AddMiettunen, J(ouko)
AddMyllyharju, J(ohanna)
AddMyllylä, R.
AddMyllylä, V.
AddNäyhä, S(imo)
AddNeubauer, P.
AddNieminen, M(iika) T.
AddNieminen, P(entti)
AddNiinimäki, J(aakko)
AddOhukainen, P(auli)
AddOikarinen, A.
AddOikarinen, K.
AddPelkonen, O(lavi)
AddPetäjä-Repo, U.E.
AddPihlajaniemi, T(aina)
AddPirttiniemi, P(ertti)
AddPuistola, U(lla)
AddRajaniemi, H.J.
AddRäsänen, P.
AddRaustia, A.
AddRemes, A(nne)
AddRisteli, J.
AddRistiniemi, J.
AddRuddock, L.W.
AddRuokonen, A.
AddRyynänen, M.
AddSaarakkala, S.
AddSaari, A.
AddSalo, T(uula)
AddSándor, G(eorge) K.
AddSavolainen, E-R.
AddSavolainen, M.J.
AddSavolainen, O.
AddSillanpää, M(ikko).
AddSoininen, R.
AddSorri, M.
AddTaanila, A.
AddTapiainen, T(erhi)
AddTervonen, O(smo)
AddTimonen, M(arkku)
AddTurpeenniemi-Hujanen, T.
AddTuukkanen, J(uha)
AddTuulonen, A.
AddUhari, M.
AddUkkola, O(lavi)
AddUusimaa, J.
AddVainio, O.
AddVainio, S.
AddVäyrynen, J(uha) P.
AddVeijola, J(uha)
AddVeijola, R(iitta)
AddVirokannas, H.
AddVoipio, H(anna)-M(arja)
AddVuolteenaho, O.
AddWeckström, M.
AddWei, GH.
AddWierenga, R.K.
AddWinqvist, R(obert)
AddYlänne, J.
AddYlitalo, K(ari)

Scholar Chart >>

»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.Turpeenniemi-Hujanen, T.579 dayssaveRefWorks
Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas.Turpeenniemi-Hujanen, T.581 dayssaveRefWorks
Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.Turpeenniemi-Hujanen, T.659 dayssaveRefWorks
Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.Turpeenniemi-Hujanen, T.733 dayssaveRefWorks
Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression.Turpeenniemi-Hujanen, T.838 dayssaveRefWorks
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.Turpeenniemi-Hujanen, T.846 dayssaveRefWorks
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.Turpeenniemi-Hujanen, T.863 dayssaveRefWorks
Incidence of solid cancer in patients with follicular lymphoma.Turpeenniemi-Hujanen, T.907 dayssaveRefWorks
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.Turpeenniemi-Hujanen, T.936 dayssaveRefWorks
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.Turpeenniemi-Hujanen, T.1076 dayssaveRefWorks
Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients; Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16).Turpeenniemi-Hujanen, T.1123 dayssaveRefWorks
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.Turpeenniemi-Hujanen, T.1206 dayssaveRefWorks
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.Turpeenniemi-Hujanen, T.1333 dayssaveRefWorks
Case Report: Chemotherapy in Conjunction With Blood-Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases.Turpeenniemi-Hujanen, T.1335 dayssaveRefWorks
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.Turpeenniemi-Hujanen, T.1405 dayssaveRefWorks
Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.Turpeenniemi-Hujanen, T.1489 dayssaveRefWorks
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.1599 dayssaveRefWorks
Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.Turpeenniemi-Hujanen, T.1629 dayssaveRefWorks
Real-time monitoring of human blood-brain barrier disruption.Turpeenniemi-Hujanen, T.1771 dayssaveRefWorks
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).Turpeenniemi-Hujanen, T.1923 dayssaveRefWorks
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.Turpeenniemi-Hujanen, T.1956 dayssaveRefWorks
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.Turpeenniemi-Hujanen, T.2065 dayssaveRefWorks
Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.Turpeenniemi-Hujanen, T.2139 dayssaveRefWorks
Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.Turpeenniemi-Hujanen, T.2389 dayssaveRefWorks
High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.Turpeenniemi-Hujanen, T.2456 dayssaveRefWorks
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.Turpeenniemi-Hujanen, T.2510 dayssaveRefWorks
Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma.Turpeenniemi-Hujanen, T.2527 dayssaveRefWorks
Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.Turpeenniemi-Hujanen, T.2852 dayssaveRefWorks
Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.Turpeenniemi-Hujanen, T.2959 dayssaveRefWorks
[Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].Turpeenniemi-Hujanen, T.3009 dayssaveRefWorks
Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma.Turpeenniemi-Hujanen, T.3133 dayssaveRefWorks
Cell cycle regulation score predicts relapse-free survival in non-germinal center diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.Turpeenniemi-Hujanen, T.3213 dayssaveRefWorks
Circulating matrix metalloproteinases MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.Turpeenniemi-Hujanen, T.3295 dayssaveRefWorks
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.Turpeenniemi-Hujanen, T.3303 dayssaveRefWorks
Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.3337 dayssaveRefWorks
Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.3343 dayssaveRefWorks
Snail promotes an invasive phenotype in lung carcinoma.Turpeenniemi-Hujanen, T.3353 dayssaveRefWorks
Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.Turpeenniemi-Hujanen, T.3584 dayssaveRefWorks
Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.Turpeenniemi-Hujanen, T.3652 dayssaveRefWorks
Long-term prognosis of breast cancer detected by mammography screening or other methods.Turpeenniemi-Hujanen, T.3679 dayssaveRefWorks
Expression and Prognostic Evaluation of Oxidative Stress Markers in an Immunohistochemical Study of B-cell Derived Lymphomas.Turpeenniemi-Hujanen, T.3778 dayssaveRefWorks
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.Turpeenniemi-Hujanen, T.3785 dayssaveRefWorks
Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma : a retrospective archival study.Turpeenniemi-Hujanen, T.3925 dayssaveRefWorks
8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.Turpeenniemi-Hujanen, T.3939 dayssaveRefWorks
A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.Turpeenniemi-Hujanen, T.3990 dayssaveRefWorks
Very high quantitative tumor HER2 content and outcome in early breast cancer.Turpeenniemi-Hujanen, T.4009 dayssaveRefWorks
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.Turpeenniemi-Hujanen, T.4017 dayssaveRefWorks
p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations.Turpeenniemi-Hujanen, T.4057 dayssaveRefWorks
Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.Turpeenniemi-Hujanen, T.4302 dayssaveRefWorks
Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.Turpeenniemi-Hujanen, T.4378 dayssaveRefWorks
 XML / RSS feed
next »